Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 1, 2009, Pages 117-131

  Pisanti, Simona ^a   Malfitano, Anna Maria ^a   Grimaldi, Claudia ^a   Santoro, Antonietta ^a   Gazzerro, Patrizia ^a   Laezza, Chiara ^b   Bifulco, Maurizio ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b CNR   (Italy)

Author keywords

cancer; cannabinoid agonists; CB receptors; inflammation; nausea; pain

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR AFFECTING AGENT; CANNABINOID RECEPTOR AGONIST; CANNABIS; DELTA8 TETRAHYDROCANNABINOL; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; METHANANDAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N ARACHIDONOYL SEROTONIN; NABILONE; PALMITOYETHANOLAMIDE; PLACEBO; PROCHLORPERAZINE; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COLON CANCER; DRUG TARGETING; GLIOBLASTOMA; HUMAN; LUNG CARCINOMA; LUNG METASTASIS; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NONHUMAN; REVIEW; THYROID TUMOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; ENDOCANNABINOIDS; HUMANS; IMMUNOSUPPRESSION; NAUSEA; NEOPLASMS; PAIN; PALLIATIVE CARE; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RISK; VOMITING;

EID: 61649089052     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2009.02.001     Document Type: Review

References (99)

1. Peters H., and Nahas G.G. A brief history of four millennia (B.C. 2000-A.D. 1974). In: Nahas G.G., Sutin K.M., Harvey D., et al. (Eds). Marihuana and medicine (1999), Humana Press, Totowa, NJ 3-7
2. Gaoni Y., and Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 86 (1964) 1646-1647
3. Howlett A.C., Barth F., Bonner T.I., et al. Classification of cannabinoid receptors. Pharmacological Reviews 54 (2002) 161-202
4. De Petrocellis L., Cascio M.G., and Di Marzo V. The endocannabinoid system: a general view and latest additions. British Journal of Pharmacology 141 (2004) 765-774
5. Di Marzo V. Endocannabinoids and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochimica et Biophysica Acta 1392 (1998) 153-175
6. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 58 (2006) 389-462
7. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
8. Howlett A.C., Qualy J.M., and Khachatrian L.L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Molecular Pharmacology 29 (1986) 307-313
9. Bouaboula M., Poinot-Chazel C., Bourrie B., et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. The Biochemical Journal 312 (1995) 637-641
10. Gomez Del Pulgar T., De Ceballos M.L., Guzman M., et al. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. The Journal of Biological Chemistry 277 (2002) 36527-36533
11. Mackie K., and Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Sciences of the United States of America 89 (1992) 3825-3829
12. Bifulco M., and Di Marzo V. The endocannabinoid system as a target for the development of new drugs for cancer therapy. Nature Medicine 8 (2002) 547-550
13. Bifulco M., Laezza C., Pisanti S., et al. Cannabinoids and cancer: pros and cons of an antitumour strategy. British Journal of Pharmacology 148 (2006) 123-135
14. Bifulco M., Malfitano A.M., Pisanti S., et al. Endocannabinoids in endocrine and related tumours. Endocrine-related Cancer 15 (2008) 391-408
15. De Petrocellis L., Melck D., Palmisano A., et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 8375-8380
16. Melck D., Rueda D., Galve-Ropher I., et al. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Letters 463 (1999) 235-240
17. Melck D., De Petrocellis L., Orlando P., et al. Suppression of nerve growth factor Trk receptor and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141 (2000) 118-126
18. Laezza C., Pisanti S., Crescenzi E., et al. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Letters 13 580 (2006) 6076-6082
19. Grimaldi C., Pisanti S., Laezza C., et al. Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research 15 312 (2006) 363-373
20. McKallip R.J., Nagarkatti M., and Nagarkatti P.S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. Journal of Immunology 15 174 (2005) 3281-3289
21. Caffarel M.M., Sarrio D., Palacios J., et al. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Research 66 (2006) 6615-6621
22. Ligresti A., Moriello A.S., Starowicz K., et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. The Journal of Pharmacology and Experimental Therapeutics 318 (2006) 1375-1387
23. Sarnataro D., Pisanti S., Santoro A., et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid rafts mediated mechanism. Molecular Pharmacology 70 (2006) 1298-1306
24. Mimeault M., Pommery N., Wattez N., et al. Antiproliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56 (2003) 1-12
25. Ruiz L., Miguel A., and Diaz-Laviada I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Letters 458 (1999) 400-404
26. Sarfaraz S., Afaq F., Adhami V.M., et al. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Research 65 (2005) 1635-1641
27. Sanchez M.G., Sanchez A.M., Ruiz-Llorente L., et al. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Letters 555 (2003) 561-566
28. Galve-Roperh I., Sanchez C., Cortes M.L., et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine 6 (2000) 313-319
29. Sanchez C., de Ceballos M.L., del Pulgar T.G., et al. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Research 61 (2001) 5784-5789
30. Ellert-Miklaszewska A., Kaminska B., and Konarska L. Cannabinoids downregulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cellular Signalling 17 (2005) 25-37
31. McAllister S.D., Chan C., Taft R.J., et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. Journal of Neuro-oncology 74 (2005) 31-40
32. Hinz B., Ramer R., Eichele K., et al. R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochemical and Biophysical Research Communications 324 (2004) 621-626
33. Bifulco M., Laezza C., Portella G., et al. Control by the endogenous cannabinoid system of ras oncogene dependent tumor growth. The FASEB Journal 15 (2001) 2745-2747
34. Portella G., Laezza C., Laccetti P., et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. The FASEB Journal 17 (2003) 1771-1773
35. Bifulco M., Laezza C., Valenti M., et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. The FASEB Journal 18 (2004) 1606-1608
36. Maccarrone M., Lorenzon T., Bari M., et al. Anandamide induces apoptosis in human cells via vanilloid receptors: evidence for a protective role of cannabinoid receptors. The Journal of Biological Chemistry 275 (2000) 31938-31945
37. McKallip R.J., Lombard C., Fisher M., et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100 (2002) 627-634
38. Flygare J., Gustafsson K., Kimby E., et al. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Letters 579 (2005) 6885-6889
39. Gustafsson K., Christensson B., Sander B., et al. Cannabinoid receptormediated apoptosis induced by R(+)-methanandamide and Win55, 212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Molecular Pharmacology 70 (2006) 1612-1620
40. Herrera B., Carracedo A., Diez-Zaera M., et al. p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. FEBS Letters 579 (2005) 5084-5088
41. Ligresti A., Bisogno T., Matias I., et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125 (2003) 677-687
42. Patsos H.A., Hicks D.J., Dobson R.R., et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 54 (2005) 1741-1750
43. Izzo A.A., Aviello G., Petrosino S., et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. Journal of Molecular Medicine 86 (2008) 89-98
44. Wang D., Wang H., Ning W., et al. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Research 68 (2008) 6468-6476
45. Casanova M.L., Blazquez C., Martinez-Palacio J., et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. The Journal of Clinical Investigation 111 (2003) 43-50
46. Munson A.E., Harris L.S., Friedman M.A., et al. Antineoplastic activity of cannabinoids. Journal of the National Cancer Institute 55 (1975) 597-602
47. Hart S., Fischer O.M., and Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Research 64 (2004) 1943-1950
48. Carracedo A., Gironella M., Lorente M., et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Research 66 (2006) 6748-6755
49. Blazquez C., Casanova M.L., Planas A., et al. Inhibition of tumor angiogenesis by cannabinoids. The FASEB Journal 17 (2003) 529-531
50. Pisanti S., Borselli C., Oliviero O., et al. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. Journal of Cellular Physiology 211 (2007) 495-503
51. Ramer R., and Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. Journal of the National Cancer Institute 100 (2008) 59-69
52. Klein T.W., Newton C., Larsen K., et al. The cannabinoid system and immune modulation. Journal of Leukocyte Biology 74 (2003) 486-496
53. Malfitano A.M., Matarese G., Pisanti S., et al. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. Journal of Neuroimmunology 171 (2006) 110-119
54. Pockaj B.A., Basu G.D., Pathangey L.B., et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Annals of Surgical Oncology 11 (2004) 328
55. Newton C.A., Klein T.W., and Friedman H. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by {up triangle, open}-9-tetrahydrocannabinol injection. Infection and Immunity 62 (1994) 4015
56. Vieweg J., Su Z., Dahm P., et al. Reversal of tumor-mediated immunosuppression. Clinical Cancer Research 13 (2007) 727s-732s
57. Zhu Li X., Sharma S., Stolida M., et al. {up triangle, open}-9-Tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. The Journal of Immunology 165 (2000) 373-380
58. Yuan M., Kiertscher S.M., Cheng Q., et al. {up triangle, open}9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. Journal of Neuroimmunology 133 (2002) 124-131
59. Xu X., Liu Y., Huang S., et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genetics and Cytogenetics 171 (2006) 31-38
60. Islam T.C., Asplund A.C., Lindvall J.M., et al. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 17 (2003) 1880-1890
61. Calatozzolo C., Salmaggi A., Pollo B., et al. Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurological Sciences 28 (2007) 304-310
62. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
63. Philip M., Rowley D.A., and Schreiber H. Inflammation as a tumor promoter in cancer induction. Seminars in Cancer Biology 14 (2004) 433-439
64. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
65. Yang C.R., Hsieh S.L., Ho F.M., et al. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-nB-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. Journal of Immunology 174 (2005) 1647-1656
66. Molina-Holgado F., Molina-Holgado E., and Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Letters 433 1-2 (1998) 139-242
67. Mazzari S., Canella R., Petrelli L., et al. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. European Journal of Pharmacology 300 3 (1996) 227-236
68. Richardson J.D., Aanonsen L., and Hargreaves K.M. Antihyperalgesic effects of spinal cannabinoids. European Journal of Pharmacology 345 2 (1998) 145-153
69. Michalski C.W., Laukert T., Sauliunaite D., et al. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology 132 5 (2007) 1968-1978
70. Massa F., Marsicano G., Hermann H., et al. The endogenous cannabinoid system protects against colonic inflammation. The Journal of Clinical Investigation 113 8 (2004) 1202-1209
71. Joseph J., Niggemann B., Zaenker K.S., et al. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunology, Immunotherapy 53 8 (2004) 723-728
72. Zheng D., Bode A.M., Zhao Q., et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Research 68 10 (2008) 3992-3998
73. Guzman M., Duarte M.J., Blazquez C., et al. A pilot clinical study of D9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer 95 (2006) 197-203
74. Bifulco M., Grimaldi C., Gazzerro P., et al. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Molecular Pharmacology 71 (2007) 1445-1456
75. Bouaboula M., Perrachon S., Milligan L., et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. The Journal of Biological Chemistry 272 (1997) 22330-22339
76. Gary-Bobo M., Elachouri G., Scatton B., et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Molecular Pharmacology 69 (2006) 471-478
77. Teixeira-Clerc F., Julien B., Grenard P., et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nature Medicine 12 (2006) 671-676
78. Walsh D., Nelson K.A., and Mahmoud F.A. Established and potential therapeutic applications of cannabinoids in oncology. Support Care in Cancer 11 (2003) 137-143
79. Andrews P.L., Naylor R.J., and Joss R.A. Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies. Support Care in Cancer 6 (1998) 197-203
80. Cichewicz D.L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sciences 74 (2004) 1317-1324
81. Carlo D., and Izzo A.A. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opinion on Investigational Drugs 12 (2003) 39-49
82. Maida V., Ennis M., Irani S., et al. Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. The Journal of Supportive Oncology 6 (2008) 119-124
83. Walsh D., Kirkova J., and Davis M.P. The efficacy and tolerability of long-term use of dronabinol in cancer-related anorexia: a case series. Journal of Pain and Symptom Management 30 (2005) 493-495
84. Meiri E., Jhangiani H., Vredenburgh J.J., et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Current Medical Research and Opinion 23 (2007) 533-543
85. Maida V. The synthetic cannabinoid Nabilone improves pain and symptom management in cancer patients. SABCS, 2006, abstract 3145.
86. Zutt M., Hänssle H., Emmert S., et al. Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases. Der Hautarzt 57 (2006) 423-427
87. Strasser F., Luftner D., Possinger K., et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology 24 (2006) 3394-3400
88. Sutton I.R., and Daeninck P. Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. The Journal of Supportive Oncology 4 (2006) 531-535
89. Jatoi A., Windschitl H.E., Loprinzi C.L., et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology 20 (2002) 567-573
90. Abrahamov A., Abrahamov A., and Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences 56 (1995) 2097-2102
91. Nelson K., Walsh D., Deeter P., et al. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. Journal of Palliative Care 10 (1994) 14-18
92. Lane M., Vogel C.L., Ferguson J., et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. Journal of Pain and Symptom Management 6 (1991) 352-359
93. Cherny N.I. The pharmacologic management of cancer pain. Oncology 18 (2004) 1499-1515
94. Walker J.M., and Huang S.M. Cannabinoid analgesia. Pharmacology & Therapeutics 95 (2002) 127-135
95. Potenzieri C., Harding-Rose C., and Simone D.A. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Research 1215 (2008) 69-75
96. Pertwee R.G. Cannabinoid receptors and pain. Progress in Neurobiology 63 (2001) 569-611
97. Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. Frontiers of Hormone Research 36 (2008) 135-145
98. Di Marzo V., Goparaju S.K., Wang L., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2002) 822-825
99. Wilson M.M., Philpot C., and Morley J.E. Anorexia of aging in long term care: is dronabinol an effective appetite stimulant?-a pilot study. The Journal of Nutrition, Health & Aging 11 (2007) 195-198